TradeUP (NASDAQ:UPTD) announced in an 8-K this afternoon that has entered into additional subscription agreements in connection with its combination with Estrella Biopharma.
Under these subscription agreements, Plentiful Limited and Lianhe World Limited, collectively known as the “Investors”, agreed to each buy $5,000,000 worth of UPTD’s common stock, priced at $10.00 per share. However, if, at the Closing, the volume weighted average price of the shares over the fifteen trading days leading up to it (referred to as the “VWAP”) falls below $8.30, each Investor has the right to receive extra shares. This extra share count is calculated as the difference between $8.30 and the VWAP at the Closing, multiplied by 100,000.
Within thirty days after the Closing, each Investor is also entitled to receive an additional 704,819 shares. Furthermore, if, on the date 24 months after the Closing (the “24-Month Date”), the VWAP of the shares for the fifteen trading days leading up to that date (the “24-Month Date VWAP”) falls below $8.30, each Investor has the right to receive more shares. The number of extra shares is determined by the difference between $8.30 and the 24-Month Date VWAP, multiplied by the difference between the number of shares held by the Investor on the 24-Month Date and the number of shares acquired by the Investor after the Closing, divided by $10.00.
TradeUp initially announced its $398 million combination with Estrella Biopharma in October 2022. The combination was approved by shareholders on July 31, 2023, but the deal is still working its way to a close. However, today’s 8-k states that the combined company’s anticipated first date of trading will be in October 2023.
Emeryville, California-based Estrella is developing three potential cancer therapies aimed at improving the effectiveness of T-cell treatments.
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...
FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...
At the SPAC of Dawn Dealmakers remain confident that AI is going to play a big role in their M&A processes, but feel unprepared for some the changes, according to a new survey of 225 corporate and 75 private equity transactions professionals. SS&C subsidiary Mergermarket generated the report that found more than half of respondents...
Trailblazer Merger I (NASDAQ:TBMC) has entered into a definitive agreement to combine with data intelligence firm Cyabra at an enterprise value of $70 million. Tel Aviv-based Cyabra provides tools to corporations and governments to identify fake accounts and combat social media disinformation. The combined company is expected to trade on the Nasdaq once the deal...
Chain Bridge I (NASDAQ:CBRG) has entered into a definitive agreement to combine with cannabinoid pharmaceuticals firm Phytanix Bio at a pre-deal valuation of $58 million. Santa Barbara, California-based Phytanix is working to develop bladder and seizure treatments using cannabis-based substances. The combined company is expected to trade on the Nasdaq under the symbol “PHYX” once...